ArticleFrontiers in immunology2025

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Zhifeng Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.